The AlphaLISA® immunoassay kit for human TDP-43 is designed for the quantitative determination of Transactive response DNA binding protein 43 (TDP43) in human serum, cerebrospinal fluid (CSF), cell lysates, cell culture supernatants using a homogeneous AlphaLISA assay (no wash steps).
true falseFor research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Formats:
Features:
TAR DNA-binding protein 43 (TDP-43, transactive response DNA binding protein 43 kDa) is a transcriptional repressor protein. Excess amounts of protein inside the nucleus of nerve cells have been reported in two fatal neurodegenerative diseases - amyotrophic lateral sclerosis (ALS), and fronto-temporal dementia (FTD). As such, it is becoming an important biomarker of neurological disease and target for intervention. This AlphaLISA kit has been designed to detect and quantify Human TDP-43 in human serum, CSF, cell culture supernatants, and cell lysates.p>
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Assay Target | TDP-43 |
---|---|
Assay Target Class | Protein |
Automation Compatible | Yes |
Detection Method | Alpha |
Experimental Type | In vitro |
Product Brand Name | AlphaLISA |
Shipping Condition | Blue Ice |
Therapeutic Area | Central Nervous System |
Unit Size | 100 assay points |
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.